$15.01
0.05[0.33%]
At close: May 15
$15.01
0[0.00%]
After Hours: 5:25PM EDT
Contineum Therapeutics
(NASDAQ:CTNM)Contineum Therapeutics Stock (NASDAQ:CTNM), Analyst Ratings, Price Targets, Predictions
Contineum Therapeutics Inc has a consensus price target of $28, established from looking at the 3 latest analyst ratings. The last 3 analyst ratings were released from Stifel, RBC Capital, and Morgan Stanley on April 30, 2024. With an average price target of $28 between Stifel, RBC Capital, and Morgan Stanley, there's an implied 86.54% upside for Contineum Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stifel
RBC Capital
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Contineum Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/30/2024 | Buy Now | 93.2% | Stifel | Paul Matteis | → $29 | Initiates | → Buy | Get Alert |
| 04/30/2024 | Buy Now | 99.87% | RBC Capital | Brian Abrahams | → $30 | Initiates | → Outperform | Get Alert |
| 04/30/2024 | Buy Now | 66.56% | Morgan Stanley | Jeffrey Hung | → $25 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Contineum Therapeutics (CTNM)?
The latest price target for Contineum Therapeutics (NASDAQ: CTNM) was reported by Stifel on April 30, 2024. The analyst firm set a price target for $29.00 expecting CTNM to rise to within 12 months (a possible 93.20% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Contineum Therapeutics (CTNM)?
The latest analyst rating for Contineum Therapeutics (NASDAQ: CTNM) was provided by Stifel, and Contineum Therapeutics initiated their buy rating.
When was the last upgrade for Contineum Therapeutics (CTNM)?
There is no last upgrade for Contineum Therapeutics.
When was the last downgrade for Contineum Therapeutics (CTNM)?
There is no last downgrade for Contineum Therapeutics.
When is the next analyst rating going to be posted or updated for Contineum Therapeutics (CTNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Contineum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Contineum Therapeutics was filed on April 30, 2024 so you should expect the next rating to be made available sometime around April 30, 2025.
Is the Analyst Rating Contineum Therapeutics (CTNM) correct?
While ratings are subjective and will change, the latest Contineum Therapeutics (CTNM) rating was a initiated with a price target of $0.00 to $29.00. The current price Contineum Therapeutics (CTNM) is trading at is $15.01, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.